3 ms·
It's also unlikely to be very effective due to it using the adenovirus Ad5 as a vector, which is a human adenovirus that many people have antibodies against. Th
by lbeltrame 6y ago
It's also unlikely to be very effective due to it using the adenovirus Ad5 as a vector, which is a human adenovirus that many people have antibodies against. This means a marked loss of efficacy if you have them.
- sudosysgen 6y agoWell, the trials show that is effective in essentially everyone. The use of the Ad5 vector does not require replication, it's therefore unlikely that antibodies will be effective at stopping a significant amount of the vector implantation of a large fraction of the viral particles in cells. If you read the study, it states that even in recipients with high Ad5 immunity, as long as the dose is sufficient (high-dose or medium dose) long-term seroconversion is high - 84% to 100% in medium or high dose after 28 days for recipients with strong antibodies against Ad5, and for high-dose seroconversion and interferon gamma response was indistinguishable from those without strong Ad5 immunity. [0, fig 1 - Specific T-cell response measured by ELISpot]. So I don't really think it will be an issue. You just need the proper dose. : https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext https://www.thelancet.com/journals/lancet/article/PIIS0140-6...
- lbeltrame 6y agoLike with Moderna, if I recall (on mobile, so I can't refresh my memory by rereading it) the highest doses had some Grade 3 level fevers. So probably medium dose would be used.
- sudosysgen 6y agoYep, side effects seem to be comparable. Medium dose would probably be used, or likely something between medium dose and high dose.